Novel AGLP-1 albumin fusion protein as a long-lasting agent for type 2 diabetes
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Glucagon like peptide-1 (GLP-1) regulates glucose mediated-insulin secretion, nutrient accumulation, and β-cell growth. Despite the potential therapeutic usage for type 2 diabetes (T2D), GLP-1 has a short half-life in vivo (t1/2 ＜2 min). In an attempt to prolong half-life, GLP-1 fusion proteins were genetically engineered: GLP-1 human serum albumin fusion (GLP-1/HSA), AGLP-1/HSA which has an additional alanine at the N-terminus of GLP-1, and AGLP-1-L/HSA, in which a peptide linker is inserted between AGLP-1 and HSA. Recombinant fusion proteins secreted from the Chinese Hamster Ovary-K1(CHO-K1) cell line were purified with high purity (＞96%). AGLP-1 fusion protein was resistant against the dipeptidyl peptidase-IV (DPP-IV). The fusion proteins activated cAMP-mediated signaling in rat insulinoma INS-1 cells. Furthermore, a C57BL/6N mice pharmacodynamics study exhibited that AGLP-1-L/HSA effectively reduced blood glucose level compared to AGLP-1/HSA.
Abstract
Glucagon like peptide-1 (GLP-1) regulates glucose mediated-insulin secretion, nutrient accumulation, and β-cell growth. Despite the potential therapeutic usage for type 2 diabetes (T2D), GLP-1 has a short half-life in vivo (t1/2 ＜2 min). In an attempt to prolong half-life, GLP-1 fusion proteins were genetically engineered: GLP-1 human serum albumin fusion (GLP-1/HSA), AGLP-1/HSA which has an additional alanine at the N-terminus of GLP-1, and AGLP-1-L/HSA, in which a peptide linker is inserted between AGLP-1 and HSA. Recombinant fusion proteins secreted from the Chinese Hamster Ovary-K1(CHO-K1) cell line were purified with high purity (＞96%). AGLP-1 fusion protein was resistant against the dipeptidyl peptidase-IV (DPP-IV). The fusion proteins activated cAMP-mediated signaling in rat insulinoma INS-1 cells. Furthermore, a C57BL/6N mice pharmacodynamics study exhibited that AGLP-1-L/HSA effectively reduced blood glucose level compared to AGLP-1/HSA.
참고문헌 (20)
- Baggio, L. L., "Biology of incretins: GLP-1 and GIP", Gastroenterology, 132, pp.2131~2157 (2007)
- Holst, J. J., "The physiology of glucagon-like peptide 1", Physiol. Rev, 87, pp.1409~1439 (2007)
- Quoyer, J., "GLP-1 mediates antiapoptotic effect by phosphorylating Bad through a β-arrestin 1-mediated ERK1", 2 activation in pancreatic β-cells, 2010, pp.285, 1989~2002
- Doyle, M., "Mechanisms of action of GLP-1 in the pancreas", Pharmacol. Ther, 113, pp.546~593 (2007)
- Jhala, U. S., "cAMP promotes pancreatic beta- cell survival via CREB-mediated induction of IRS2", Genes Dev, 17, pp.1575~1580 (2003)
- Kodama, S., "Enhanced expression of PDX-1 and Ngn3 by exendin-4 during β cell regeneration in STZ-treated mice", Biochem. Biophysic. Res. Comm, 327, pp.1190~1196 (2005)
- Zhou, J., "Purification and bioactivity of exendin- 4, a peptide analogue of GLP-1, expressed in pichia pastoris", Biotechnol. Lett, 30, pp.651~656 (2008)
- Gao, Z., "Development, characterization, and evaluation of a fusion protein of a novel glucagon-like peptide- 1 (GLP-1) analog and human serum albumin in pichia pastoris", Biosci. Biotechnol. Biochem, 73, pp.688~694 (2009)
- Ji-Yeon Oh, "Novel DPP-IV-resistant Analogs of GLP-1: The N-terminal Extension of GLP-1 by a Single Amino Acid", Bulletin of the Korean Chemical Society, 30(10), pp.2471~2474 (2009), 대한화학회
- Garber, A. J., "Long-acting glucagon-like peptide 1receptor agonists", Diabetes Care, 34, pp.S279~S284 (2011)
- Liu, B., "Preparation, characterization, and pharmacodynamics of exenatide-loaded poly (DL-lactic-co-glycolic acid) microspheres", Chem. Pharm. Bull, 58, pp.1474~1479 (2010)
- Baggio, L. L., "A recombinant human glucagon-like peptide(GLP)-1-albumin protein(Albugon)mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis", Diabetes, 53, pp.2492~2500 (2004)
- Huang, Y. S., "Preparation and characterization of a novel exendin-4 human serum albumin fusion protein expressed in Pichia pastoris", J. Pept. Sci, 14, pp.588~595 (2008)
- Kim, B. J., "Transferrin fusion technology: A novel approach to prolonging biological half-life of insulinotropic peptides", J. Pharm. Exp. Ther, 334, pp.682~692 (2010)
- Wang Q, Chen, K., "Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist", PLoS One, 5, pp.e12734 1~e12734 9 (2010)
- 박은정, "Effects of novel chalcone derivatives on α-glucosidase, dipeptidyl peptidase-4, and adipocyte differentiation in vitro", BMB Reports, 44(6), pp.410~414 (2011), 생화학분자생물학회
- Neumiller, J. J., "Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors", J. American Pharm. Associ, 49, pp.S16~S29 (2009)
- Jin-A Yeom, "Both sitagliptin analogue & pioglitazone preserve the β-cell proportion in the islets with different mechanism in non-obese and obese diabetic mice", BMB Reports, 44(11), pp.713~718 (2011), 생화학분자생물학회
- Chung, H. S., "The N-terminal alanine-extended GLP-1", IgG-Fc fusion protein confers resistance to DPP-IV and reduces serum glucose level in db, Regul. Pept, pp.2011, 170[DOI]
- Youn Kyoung Son, "Direct effect of protein kinase C inhibitors on cardiovascular ion channels", BMB Reports, 44(9), pp.559~565 (2011), 생화학분자생물학회